Actively Recruiting
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Led by Hebei Medical University Fourth Hospital · Updated on 2023-09-28
20
Participants Needed
1
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug chemotherapy in the first-line treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic. Meanwhile, Related biomarkers were explored to provide theoretical basis for efficacy evaluation and resistance mechanism.
CONDITIONS
Official Title
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with metastatic (stage IV) lung adenocarcinoma not previously treated systematically and unable to have radical surgery or radiotherapy
- Brain metastases confirmed by imaging
- Asymptomatic brain metastases after initial diagnosis, local surgery, or radiotherapy
- ECOG performance status of 0 to 1
- Measurable target lesions outside the skull according to RECIST 1.1
- Life expectancy longer than 3 months
You will not qualify if you...
- Prior treatment with immune checkpoint inhibitors such as anti-PD-1, PD-L1, or CTLA-4 therapies
- Previous systemic chemotherapy for advanced cancer
- Presence of EGFR mutation or ALK gene translocation
- Use of systemic anticancer therapy or immunomodulators within 4 weeks before starting treatment
- Uncontrolled pleural fluid or ascites requiring drainage within 2 weeks before starting treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital)
Shijiazhuang, Hebei, China
Actively Recruiting
Research Team
J
Jian Shi, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here